Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
The company has received approval from DCGI to begin patient enrolment and dosing in the country
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Marksans Pharma gets USFDA nod for acid reflux drug
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
Subscribe To Our Newsletter & Stay Updated